Atlas Trials

Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma

Clinical trial NCT05355168 · COMPLETED

Trial details

NCT number
NCT05355168
Sponsor
Anhui Provincial Hospital
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Toxicity, Drug
Start date
2021-11-01
Primary completion
2023-12-31
Enrollment
35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.